This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Synageva BioPharma™ Highlights Data Presentations And Satellite Symposium At The European Atherosclerosis Society Congress

LEXINGTON, Mass., June 3, 2014 /PRNewswire/ --  Synageva BioPharma Corp. (Synageva) (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, today announced data presentations and a company-sponsored satellite symposium at the European Atherosclerosis Society (EAS) Congress being held May 31-June 3, 2014 in Madrid, Spain. 

Logo -

Sebelipase alfa continues to improve disease-related abnormalities at two years from an ongoing Phase 1/2 trial in adults with LAL Deficiency

As part of an oral presentation, Radhika Tripuraneni, M.D., M.P.H., Senior Medical Director at Synageva, provided an update to the study.  With six of the eight patients enrolled in the ongoing Phase 1/2 extension study completing two years of treatment, sebelipase alfa continued to demonstrate sustained reductions in the biomarkers of liver damage (both ALT and AST), frequently into the normal range, from the pre-treatment baseline to two years of the extension study.  Sebelipase alfa also maintained improvements in dyslipidemia associated with LAL Deficiency, with decreases in LDL and triglycerides and increases in HDL from the pre-treatment baseline to two years of the extension study. 

Sebelipase alfa was generally well tolerated through two years of the extension study.  Most adverse events were mild and unrelated to sebelipase alfa.  Infusion associated reactions were uncommon, generally mild and gastrointestinal in nature (diarrhea, abdominal cramping).  No anti-drug antibodies have been detected and no drug-related serious adverse events have been reported in this study to date.  Two serious adverse events (cholecystitis/cholelithiasis) considered unlikely related to sebelipase alfa occurred in one patient and this patient continues treatment with sebelipase alfa in the study.

Satellite Symposium and Poster Presentation at EAS

Synageva sponsored a satellite symposium at the EAS on Saturday, May 31 at 12:00 p.m.–1:30 p.m., CEST.  The symposium entitled "Elevated LDL: Not Always Familial Hypercholesterolemia; Three Mystery Cases to Diagnose" was chaired by Emilio Ros, M.D., Lipid Clinic, Endocrinology & Nutrition Service, Institut d'Investigacions Biomediques August Pi Sunyer, Hospital Clinic, Barcelona, Spain.

In addition, Synageva announced the following as a poster presentation:

"Identification, Lipoprotein Profiling and Treatment of Patients with Lysosomal Acid Lipase Deficiency", E.O. Stock, et al.

Sebelipase alfa for LAL Deficiency

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.79 0.10%
FB $101.98 0.07%
GOOG $682.32 -0.12%
TSLA $150.99 0.35%
YHOO $27.04 1.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs